CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Pete O'Heeron

Chairman, Founder and Chief Executive Officer, FibroBiologics

Search every verified Pete O'Heeron interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Pete O'Heeron, chairman, founder, and CEO of Fibrobiologics, recently appeared in multiple investor and industry forums to discuss the company's fibroblast-based cell therapy platform. In a September 22, 2026 RedChip webinar, he and Chief Scientific Officer Dr. Hamid Khoja described the company's allogeneic approach, which they said allows one donor to treat many patients with low rejection risk and manufacturing costs. O'Heeron also stated that the company expects six-week interim data from its diabetic foot ulcer trial before the end of the year, with patient recruitment described as encouraging. In a September 10, 2026 RedChip interview, O'Heeron argued that fibroblasts outperform stem cells in potency and immune modulation, citing the role of fibroblasts in Dr. Shinya Yamanaka's Nobel Prize-winning work on induced pluripotent stem cells. He also discussed the company's thymus regeneration program, claiming that the thymus begins declining around age 16 and that fibroblast-based organoids could restore its function. At the H-SPAN Summit D.C. on September 9, 2026, O'Heeron presented data on thymus organoids, stating they self-assemble in culture, can be transplanted via injection, and have shown signs of functional T-cell development in preclinical studies. He also cited statistics on chronic disease prevalence and healthcare costs, attributing a large share of U.S. spending to chronic conditions and suggesting that cell therapy represents a path toward cures.

Recent appearances

  • The Fibroblast Answer to $4T in Chronic Disease | CEO Pete O'Heeron on Fibrobiologics (Nasdaq: FBLG)

    September 23, 2026 · 📺 RedChip Companies

    CEO Pete O'Heeron and Chief Scientific Officer Dr. Hamid Khoja join RedChip to detail how FibroBiologics (Nasdaq: FBLG) is building a fibroblast-based cell therapy platform aimed at chronic diseases that remain uncured despite decades of pharmaceutical innovation. Fibroblasts are the most abundant cell type in the body, yet they have long been overlooked in favor of immune cells and stem cells. FibroBiologics' allogeneic approach allows one donor to treat many patients, with low rejection risk, low manufacturing costs, and a scalable spheroid delivery platform. Because fibroblasts are already…

    Watch on YouTube ↗

  • One Solution, Five Disease Pathways: CEO Pete O'Heeron on Fibrobiologic's (Nasdaq: FBLG) Fibroblast

    September 10, 2026 · 📺 RedChip Companies

    CEO Pete O'Heeron joins RedChip to explain why FibroBiologics (Nasdaq: FBLG) believes fibroblasts, not stem cells, represent the next major platform in regenerative medicine. FibroBiologics is a clinical-stage biotech built around a simple but underappreciated fact: fibroblasts, the cell type behind Dr. Shinya Yamanaka's Nobel Prize-winning discovery of induced pluripotent stem cells, appear to be more potent and more immune-modulating than the stem cells they helped create. They also outnumber stem cells roughly 5,000 to 1 in the human body. Rather than building around a single drug candidat…

    Watch on YouTube ↗

  • H-SPAN Summit D.C. 2026 | Pete O'Heeron - FibroBiologics

    September 09, 2026 · 📺 The Alliance for Longevity Initiatives

    Immune function declines with age in ways that raise infection risk, weaken the body's surveillance against cancer, and blunt response to vaccines. This presentation focuses on an organ that gets little attention relative to its role in building and training the immune system, on why its decline begins far earlier in life than most people assume, and on what restoring its function could mean for healthspan.

    Watch on YouTube ↗

  • Pete O’Heeron on Fibroblasts, Cell Therapy, and Building What Others Overlook

    August 03, 2026 · 📺 Entrepreneurs, Executives, and Eccentrics

    In this episode, FibroBiologics founder and CEO Pete O’Heeron shares how a career spanning hospital administration, medical devices, music, mining, and biotechnology shaped his approach to entrepreneurship. He explains the company’s work with fibroblast cells as a potential therapy for chronic disease and tissue regeneration, including the early research that led him to explore their use in spinal discs. Pete also discusses how he evaluates inventions, tests product demand, builds patent portfolios, and turns early ideas into marketable technologies. Throughout the conversation, he outlines th…

    Watch on YouTube ↗

  • Unlocking The Therapeutic Power Of Fibroblasts With Pete O’Heeron And Hamid Khoja, Ph.D.

    February 24, 2026 · 📺 Life Science Connect

    In this episode of “Better Biopharma,” host Tyler Menichiello is joined by FibroBiologics’ CEO and Founder, Pete O’Heeron, and chief scientific officer, Hamid Khoja, Ph.D. They discuss the powerful but often overlooked fibroblast, a type of connective-tissue cell that has tremendous therapeutic potential, according to O’Heeron and Khoja. They explain the company’s mission to realize this therapeutic potential and make fibroblasts a mainstay in the cell therapy space, rivaling the prominence of stem cells. Follow Tyler Menichiello on LinkedIn:   / tmenichiello   Keep up with everything bioman…

    Watch on YouTube ↗

  • Inside FibroBiologics: CEO Pete O'Heeron on Pioneering Cell Therapies for Major Disease Markets

    July 07, 2025 · 📺 RedChip Companies

    FibroBiologics (NASDAQ: FBLG) is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. FibroBiologics is a client of RedChip. Visit RedChip.com to learn…

    Watch on YouTube ↗

  • Interview with FibroBiologics CEO Pete O'Heeron

    June 26, 2024 · 📺 HealthBiz Podcast with David E. Williams

    Tune in to this informative episode with Pete O'Heeron, CEO of FibroBiologics, as we explore his journey from a small, innovative town to the forefront of healthcare innovation. Pete shares how his upbringing in a medically inclined family and a community rich with inventiveness influenced his career. Hear how Pete transitioned from pre-med to hospital administration due to unforeseen geopolitical events, ultimately finding his passion within the healthcare industry. Pete recounts his transformative experience at Christus, a multi-billion dollar hospital system, where his pivot from hospita…

    Watch on YouTube ↗

  • Fibroblasts and the Forefront of Regenerative Medicine w/ CEO, Pete O'Heeron | HealthBiz Briefs

    June 19, 2024 · 📺 CareTalk: Healthcare. Unfiltered. Podcast

    Are stem-cell treatments the future of self-therapy and regenerative medicine? Or is there something better? In the latest episode of HealthBiz Briefs, host, David Williams, is joined by Pete O’Heeron, CEO of Fibrobiologics, explores the untapped potential of fibroblasts and their promise as a potentially superior and more affordable alternative to traditional stem-cell treatments. 🎙️⚕️ABOUT CARETALK CareTalk is a weekly podcast that provides an incisive, no B.S. view of the US healthcare industry. Join co-hosts John Driscoll (President U.S. Healthcare and EVP, Walgreens Boots Alliance) and…

    Watch on YouTube ↗

  • "The Cure for Cancer is Coming" Pete O'Heeron

    March 27, 2024 · 📺 Grant Mitterlehner

    Episode #76: Pete O'Heeron is one of the preeminent Biopharma inventors of his generation with over 300+ patents issued/pending in biologics, cell therapy and medical devices. As the Founder and CEO of FibroBiologics, he brings 25 years of entrepreneurial experience in developing therapeutics to treat chronic diseases and regenerative medicine using fibroblasts. In 2024, Pete took FibroBiologics public at over 1 billion dollars. In this engaging conversation we discuss fibroblasts, stem cell recovery, the cure for cancer, entrepreneurship, and more. The Grant Mitt Podcast #76 For more info…

    Watch on YouTube ↗

  • Fibroblast Revolution and Visionary Leadership - with Pete O’Heeron

    January 07, 2024 · 📺 Brilliance Within Coaching

    In this episode of "Conversations Life Science Leaders Aren't Having," we're joined by Pete O’Heeron, a notable figure in the life sciences sector, who leads groundbreaking advancements in cell therapy, focusing on fibroblasts at Fibrobiologics. Pete discusses his company's innovative work, highlighting the potential of fibroblasts over stem cells in tissue regeneration and the treatment of chronic diseases. He sheds light on the relative obscurity of fibroblasts compared to the widely known stem cells, despite fibroblasts significantly outnumbering them in the human body. This revelation pres…

    Watch on YouTube ↗

  • Pete O’Heeron - CEO, FibroBiologics - Developing & Commercializing Fibroblast Cell-Based Therapies

    October 24, 2023 · 📺 Progress, Potential, and Possibilities

    Pete O’Heeron, MSHA, is the CEO of FibroBiologics ( https://fibrobiologics.com/ ), a biopharmaceutical company focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. Mr. O’Heeron has over 25 years of medical technology and biotech development experience and brings together the resources necessary to commercialize unique technologies with expertise from business start-ups and biologics, to medical devices and patient centered healthcare delivery. Prior to founding FibroBiologics, Mr. O’Heeron founded an operational investment…

    Watch on YouTube ↗

  • #10 - Pete O'Heeron, Chairman/CEO/Founder, FibroBiologics

    July 27, 2023 · 📺 Slice of Healthcare Network

    Join us on the latest episode! Our Guest: Pete O'Heeron, Chairman/CEO/Founder, FibroBiologics What you'll get out of this episode: Pete's background Overview of FibroBiologics Their fibroblast technology platform and its therapeutic potential What his formula has been for growing and scaling the team and product pipeline Key takeaways from #BIO2023 What trends do he sees developing right now in regenerative medicine that will continue through the end of 2023 What's next? To learn more about FibroBiologics: https://fibrobiologics.com/ Full Episode and more info here: https://sliceofhealthc…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →